Oncology Institute, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Jorey Chernett has reported beneficial ownership of 10.2% of Oncology Institute, Inc.'s common stock as of March 13, 2026.
NASDAQ
Jorey Chernett has reported beneficial ownership of 5.2% of the common stock of Oncology Institute, Inc. in a Schedule 13G filing.
NASDAQ
SCHEDULE 13G/A: FOG Ventures Investments and Daniel Murillo Announce Full Divestment of Oncology Institute Shares
FOG Ventures Investments, LLC and Daniel Murillo have filed an amended Schedule 13G, confirming their complete exit from beneficial ownership of Oncology Institute, Inc. common stock.